Literature DB >> 28761402

Posterior Reversible Encephalopathy Syndrome after Heart Transplantation: Diagnosis and Immunosuppressive Therapy.

Aniruddh Kapoor, Emma Birks, Andrew Lenneman, Kelly McCants.   

Abstract

Posterior reversible encephalopathy syndrome, an infrequent neurotoxicity associated with the use of tacrolimus, was first described in 1996, as a reversible syndrome manifested by headache, altered mental function, seizures, and visual disturbances. We describe the case of a 37-year-old woman who developed neurologic symptoms consistent with encephalopathy after treatment with tacrolimus, which was prescribed to maintain immunosuppression after orthotopic heart transplantation. This report also discusses the imaging methods used in the diagnosis of posterior reversible encephalopathy and highlights the difficulty of maintaining immunosuppression and managing medication-related adverse effects, while taking into account the risk of acute rejection after transplantation.

Entities:  

Keywords:  Brain diseases/diagnostic imaging; drug therapy, combination; graft rejection/heart transplantation/adverse effects; immunosuppressive agents/therapeutic use; nervous system diseases/chemically induced; tacrolimus/adverse effects/therapeutic use; treatment outcome

Mesh:

Substances:

Year:  2017        PMID: 28761402      PMCID: PMC5505400          DOI: 10.14503/THIJ-15-5007

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  18 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

2.  Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management.

Authors:  M Roy First; David A Gerber; Sundaram Hariharan; Dixon B Kaufman; Ron Shapiro
Journal:  Transplantation       Date:  2002-02-15       Impact factor: 4.939

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 4.  Risk for posttransplant Diabetes mellitus with current immunosuppressive medications.

Authors:  M R Weir; J C Fink
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

5.  A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.

Authors:  David A Baran; Mark J Zucker; Luis H Arroyo; Margarita Camacho; Marc E Goldschmidt; Stephen J Nicholls; Jeanne Prevost-Fernandez; Candace Carr; Laura Adams; Susan Pardi; Vera Hou; Maria Binetti; Jeanine McCahill; Joanne Chichetti; Valerie Viloria; Mary Gladys Sanagustin; Jennifer Ebuenga-Smith; Leslie Mele; Anthony Martin; Donna Blicharz; Kathy Wolski; Ludmilla Olesnicky; Fang Qian; Alan L Gass; Marc Cohen
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

6.  Life-threatening complications of posterior reversible encephalopathy syndrome in children.

Authors:  Duccio M Cordelli; Riccardo Masetti; Emilia Ricci; Francesco Toni; Daniele Zama; Monica Maffei; Andrea Gentili; Antonia Parmeggiani; Andrea Pession; Emilio Franzoni
Journal:  Eur J Paediatr Neurol       Date:  2014-04-25       Impact factor: 3.140

7.  Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression.

Authors:  E F Wijdicks; R H Wiesner; R A Krom
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

8.  Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation.

Authors:  A S Barbas; A S Rege; A W Castleberry; J Gommer; M J Ellis; T V Brennan; B H Collins; A E Martin; K V Ravindra; D S Vikraman; D L Sudan
Journal:  Am J Transplant       Date:  2013-01-17       Impact factor: 8.086

9.  Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.

Authors: 
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

10.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

Authors: 
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

View more
  1 in total

1.  Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.

Authors:  Julián Alejandro Rivillas; Stephania Galindo-Coral; Francisco Arias-Mora; Juan David Lopez-Ponce de Leon; Noel Alberto Florez-Alarcón; Pastor Olaya-Rojas; Juan Esteban Gomez-Mesa
Journal:  Case Rep Cardiol       Date:  2021-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.